Last reviewed · How we verify

NCT05971498

Assessment of Anxiety, Depression, Sleep Quality and Quality of Life in Systemic Lupus Erythematosus Patients

Status unknown Last updated 18 September 2023
What this trial tests

trial in Systemic Lupus Erythematosus in 62 participants. Status unknown.

Timeline
14 August 2023
Primary endpoint
1 February 2024
1 March 2024

Quick facts

Lead sponsorAssiut University
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment62
Start date14 August 2023
Primary completion1 February 2024
Estimated completion1 March 2024
Sites1 location across Egypt

Conditions studied

Sponsor

Assiut University

Who can join

18 and older, any sex, with Systemic Lupus Erythematosus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this case control observational study is to asses anxiety, sleep, depression and quality of life in Systemic Lupus Erythematosus (SLE) patients. The main aims are: * asses anxiety, sleep, depression and quality of life in SLE patients * their relation to disease activity we will compare SLE patients to healthy subjects.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Systemic Lupus Erythematosus

Currently open trials in the same condition.

Other Assiut University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05971498.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing